A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

I4T-MC-JVCZ -

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Stomach Cancer
What the trial is testing?
Paclitaxel, Ramucirumab
Could I receive a Placebo?
No
Enrollment Goal
245
Trial Dates
Oct 12, 2015 - Dec 28, 2018
How long will I be in the trial?
You can participate in this study for as long as your study doctor determines that you are benefiting from the study treatment.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.